Workshop proceedings: Challenges and opportunities in evaluating protein allergenicity across biotechnology industries

International Journal of Toxicology

Volumn 32, Issue 1, 2013, Pages 4-10

  Stagg, Nicola J ^a   Ghantous, Hanan N ^b   Ladics, Gregory S ^c   House, Robert V ^d   Gendel, Steven M ^b   Hastings, Kenneth L ^e  

^a Agensys   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c DUPONT COMPANY   (United States)

^d DynPort Vaccine Company LLC   (United States)

^e Sanofi SA   (United States)

Author keywords

allergenicity; biotechnology; immunotoxicity; protein

Indexed keywords

FOOD ALLERGEN; IMMUNOGLOBULIN E;

ALLERGENICITY; BIOINFORMATICS; BIOTECHNOLOGY; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; FOOD ALLERGY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MEDICAL SOCIETY; NONHUMAN; PROTEIN ALLERGENICITY; REVIEW; SEROLOGY; UNITED STATES; VACCINATION; WORKSHOP;

ALLERGENS; ANIMALS; BIOTECHNOLOGY; HUMANS; HYPERSENSITIVITY; PROTEINS;

EID: 84873683136     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581812471864     Document Type: Review

References (32)

1. Biotechnology Industry Organizationhttp://www.bio.org. Accessed November 28, 2012.
2. Pathak S, Palan U. Immunology: Essential and Fundamental. Enfield, NH: Science Publishers Inc ; 2005: 308.
3. Burks AW, Sampson HA Food Allergy: Adverse Reactions to Foods and Food Additives. Metcalfe DD Sampson HA Simon RA, ed. Cambridge, MA: Blackwell Science ; 1997: 25.
4. Goodman RE, Leach JN. Assessing the allergenicity of proteins introduced into genetically modified crops using specific human IgE assays. J AOAC Int. 2004 ; 87 (6). 1423-1432
5. Ladics GS. Current codex guidelines for assessment of potential protein allergenicity. Food Chem Toxicol. 2008 ; 46 (suppl 10). S20 - S23
6. Sampson HA Food Allergy: Adverse Reactions to Foods and Food Additives. Metcalfe DD Sampson HA Simon RA., ed. Cambridge, MA: Blackwell Science ; 1997: 169.
7. Alinorm 03/34: Joint FAO/WHO Food Standard Programme, Codex Alimentarious Commission, Twenty-Fifth Session, Rome, Italy, June30-July5, 2003.. 2003 ;: 47
8. Thomas K, Aalbers M, Bannon GA, et al. A multi-laboratory evaluation of a common in vitro pepsin digestion assay protocol used in assessing the safety of novel proteins. Regul Toxicol Pharmacol. 2004 ; 39 (2). 87-98
9. Guidance for risk assessment of food and feed from genetically modified plants. EFSA J. 2011 ; 9 (5). 2150
10. Ladics GS, Cressman R, Herouet-Guicheney C, et al. Bioinformatics and the allergy assessment of agricultural biotechnology products: industry practices and recommendations. Regul Toxicol Pharmacol. 2011 ; 60 (1). 46-53
11. Zuidmeer L, van Leeuwen WA, Kleine Budde I, et al. Allergenicity assessment of apple cultivars: hurdles in quantifying labile fruit allergens. Allergy Immunol. 2006 ; 141 (3). 230-240
12. Ahrazem O, Jimeno L, López-Torrejón G, et al. Assessing allergen levels inpeach and nectarine cultivars. Ann Allergy Asthma Immunol. 2007 ; 99 (1). 42-47
13. Salekdeh GH, Komatsu S. Crop proteomics: aim at sustainable agriculture of tomorrow. Proteomics. 2007 ; 7 (16). 2976-2996
14. Ariyarathna H, Pramod SN, Goodman RE. The abundance of lipid transfer protein (LTP), the major food allergen of corn, varies between hybrids and growth conditions. J Allergy Clin Immunol. 2009 ; 123 (2). S28
15. Kuppannan K, Albers DR, Schafer BW, Dielman D, Young SA. Quantification and characterization of maize lipid transfer protein, a food allergen, by liquid chromatography with ultraviolet and mass spectrometric detection. Anal Chem. 2010 ; 83 (2). 516-524
16. Houston NL, Lee DG, Stevenson SE, et al. Quantitation of soybean allergens using tandem mass spectrometry. J Proteome Res. 2011 ; 10 (2). 763-773
17. Stevenson SE, Woods CA, Hong B, et al. Environmental effects on allergen levels in commercially grown non-genetically modified soybeans: assessing variation across North America. Front Plant Sci. 2012 2012 ; 3 (196). 1-13
18. Ricroch AE, Berge JB, Kuntz M. Evaluation of genetically engineered crops using transcriptomic, proteomic and metabolomic profiling techniques. Plant Physiol. 2011 ; 155 (4). 1752-1761
19. Metcalfe DD, Astwood JD, Townsend R, Sampson HA, Taylor SL, Fuchs RL. Assessment of the allergenic potential of foods from genetically engineered crop plants. Crit Rev Food Sci Nutr. 1996 ; 36 (suppl). 165-186
20. Italy: Rome ; 2001 :
21. Fritsche PJ, Helbling A, Ballmer-Weber BK. Vaccine hypersensitivity - update and overview. Swiss Med Wkly. 2010 ; 140 (17-18). 238-246
22. Hauguel TM, Hackett CJ.. Rationally-designed vaccine adjuvants: separating efficacy from toxicity. Front Biosci. 2008 ; 13(8): 2806-2813
23. Siegrist CA. Mechanisms underlying adverse reactions to vaccines. J Comp Path. 2007 ; 137 (suppl 1). S46 - S50
24. Koenig HC, Sutherland A, Izurieta HS, McGonagle D. Application of the immunological disease continuum to study autoimmune and other inflammatory events after vaccination. Vaccine. 2011 ; 29 (5). 913-919
25. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008 ; 358 (23). 2457-2467
26. Kenter MJH, Cohen AF. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet. 2006 ; 368 (9544). 1387-1391
27. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents. J Am Coll Cardiol. 2006 ; 47 (1). 175-181
28. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpes viruses and antiviral and antidrug immune responses. Allergol Int. 2006 ; 55 (1). 1-8
29. US FDA. Draft Guidance for industry: quality considerations in demonstrating biosimilarity to a reference product. 2012.
30. US FDA. Draft Guidance for industry: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. 2012.
31. US FDA. Draft Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. 2012.
32. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004 ; 351 (14). 1403-1408